Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) Meeting Abstract
| Authors: | Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; Hirata, J.; Choudhry, P.; Chang, Y. M.; Musick, L.; McMillan, A. |
| Abstract Title: | Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302013 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7551 |
| Notes: | Meeting Abstract: 7551 -- Meeting also held virtually -- Source: Wos |
